Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Aging Cell ; 20(1): e13288, 2021 01.
Article in English | MEDLINE | ID: mdl-33336885

ABSTRACT

Morphological change is an explicit characteristic of cell senescence, but the underlying mechanisms remains to be addressed. Here, we demonstrated, after a survey of various actin-binding proteins, that the post-translational up-regulation of cofilin-1 was essential for the reduced rate of actin depolymerization morphological enlargement in senescent cells. Additionally, up-regulated cofilin-1 mainly existed in the serine-3 phosphorylated form, according to the 2D gel immunoblotting assay. The up-regulation of cofilin-1 was also detected in aged mammalian tissues. The over-expression of wild-type cofilin-1 and constitutively phosphorylated cofilin-1 promoted cell senescence with an increased cell size. Additionally, senescent phenotypes were also reduced by knockdown of total cofilin-1, which led to a decrease in phosphorylated cofilin-1. The senescence induced by the over-expression of cofilin-1 was dependent on p27Kip1 , but not on the p53 and p16INK4 expressions. The knockdown of p27Kip1 alleviated cell senescence induced by oxidative stress or replicative stress. We also found that the over-expression of cofilin-1 induced the expression of p27Kip1 through transcriptional suppression of the transcriptional enhancer factors domain 1 (TEAD1) transcription factor. The TEAD1 transcription factor played a transrepressive role in the p27Kip1  gene promoter, as determined by the promoter deletion reporter gene assay. Interestingly, the down-regulation of TEAD1 was accompanied by the up-regulation of cofilin-1 in senescence. The knockdown and restoration of TEAD1 in young cells and old cells could induce and inhibit p27Kip1 and senescent phenotypes, respectively. Taken together, the current data suggest that cofilin-1/TEAD1/p27Kip1 signaling is involved in senescence-related morphological change and growth arrest.


Subject(s)
Cofilin 1/metabolism , Proliferating Cell Nuclear Antigen/metabolism , Cellular Senescence , Humans , Up-Regulation
2.
Toxicol Sci ; 149(2): 277-88, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26518054

ABSTRACT

The heavy metal lead (Pb) has a deleterious effect on skeletal health. Because bone mass is maintained through a balance of bone formation and resorption, it is important to understand the effect of Pb levels on osteoblastic and osteoclastic activity. Pb exposure is associated with low bone mass in animal models and human populations; however, the correlation between Pb dosing and corresponding bone mass has been poorly explored. Thus, mice were exposed to increasing Pb and at higher levels (500 ppm), there was unexpectedly an increase in femur-tibial bone mass by 3 months of age. This is contrary to several studies alluded to earlier. Increased bone volume (BV) was accompanied by a significant increase in cortical thickness of the femur and trabecular bone that extended beyond the epiphyseal area into the marrow cavity. Subsequent evaluations revealed an increase in osteoclast numbers with high Pb exposure, but a deficiency in osteoclastic activity. These findings were substantiated by observed increases in levels of the resorption-altering hormones calcitonin and estrogen. In addition we found that pro-osteoclastic nuclear factor-kappa beta (NF-κB) pathway activity was dose dependently elevated with Pb, both in vivo and in vitro. However, the ability of osteoclasts to resorb bone was depressed in the presence of Pb in media and within test bone wafers. These findings indicate that exposure to high Pb levels disrupts early life bone accrual that may involve a disruption of osteoclast activity. This study accentuates the dose dependent variation in Pb exposure and consequent effects on skeletal health.


Subject(s)
Bone Density/drug effects , Lead/toxicity , Osteoclasts/drug effects , Adipocytes/drug effects , Aging , Animals , Female , Mice , Mice, Inbred C57BL , NF-kappa B/physiology , Osteoclasts/physiology , Osteogenesis/drug effects , Signal Transduction/drug effects , Tensile Strength/drug effects
3.
J Biol Chem ; 290(29): 18216-18226, 2015 Jul 17.
Article in English | MEDLINE | ID: mdl-25975268

ABSTRACT

Exposure to lead (Pb) from environmental sources remains an overlooked and serious public health risk. Starting in childhood, Pb in the skeleton can disrupt epiphyseal plate function, constrain the growth of long bones, and prevent attainment of a high peak bone mass, all of which will increase susceptibility to osteoporosis later in life. We hypothesize that the effects of Pb on bone mass, in part, come from depression of Wnt/ß-catenin signaling, a critical anabolic pathway for osteoblastic bone formation. In this study, we show that depression of Wnt signaling by Pb is due to increased sclerostin levels in vitro and in vivo. Downstream activation of the ß-catenin pathway using a pharmacological inhibitor of GSK-3ß ameliorates the Pb inhibition of Wnt signaling activity in the TOPGAL reporter mouse. The effect of Pb was determined to be dependent on sclerostin expression through use of the SOST gene knock-out mice, which are resistant to Pb-induced trabecular bone loss and maintain their mechanical bone strength. Moreover, isolated bone marrow cells from the sclerostin null mice show improved bone formation potential even after exposure to Pb. Also, our data suggest that the TGFß canonical signaling pathway is the mechanism by which Pb controls sclerostin production. Taken together these results support our hypothesis that the osteoporotic-like phenotype observed after Pb exposure is, in part, regulated through modulation of the Wnt/ß-catenin pathway.


Subject(s)
Environmental Pollutants/toxicity , Gene Expression Regulation/drug effects , Lead/toxicity , Osteogenesis/drug effects , Wnt Signaling Pathway/drug effects , Adaptor Proteins, Signal Transducing , Animals , Bone and Bones/anatomy & histology , Bone and Bones/drug effects , Bone and Bones/metabolism , Cell Line , Cells, Cultured , Environmental Exposure/adverse effects , Glycogen Synthase Kinase 3/antagonists & inhibitors , Glycogen Synthase Kinase 3 beta , Glycoproteins/genetics , Intercellular Signaling Peptides and Proteins , Male , Mice , Mice, Knockout , Osteoblasts/cytology , Osteoblasts/drug effects , Osteoblasts/metabolism , Smad3 Protein/metabolism , Transforming Growth Factor beta/metabolism , beta Catenin/metabolism
4.
PLoS One ; 8(9): e74255, 2013.
Article in English | MEDLINE | ID: mdl-24058535

ABSTRACT

Parathyroid hormone (PTH) plays a critical role in the regulation of chondrogenesis. In this study, we have found for the first time that Runt-related transcription factor 1 (Runx1) contributes to PTH-induced chondrogenesis. Upon PTH treatment, limb bud mesenchymal progenitor cells in micromass culture showed an enhanced chondrogenesis, which was associated with a significant increase of chondrogenic marker gene expression, such as type II collagen and type X collagen. Runx1 was also exclusively expressed in cells treated with PTH at the onset stage of chondrogenesis. Knockdown of Runx1 completely blunted PTH-mediated chondrogenesis. Furthermore, PTH induced Runx1 expression and chondrogenesis were markedly reduced by inhibition of protein kinase A (PKA) signaling. Taken together, our present study indicates that chondrogenesis induced by PTH in mesenchymal progenitor cells is mediated by Runx1, which involves the activation of PKA. These data provide a novel insight into understanding the molecular mechanisms behind PTH-enhanced cartilage regeneration.


Subject(s)
Chondrocytes/metabolism , Chondrogenesis/genetics , Core Binding Factor Alpha 2 Subunit/genetics , Cyclic AMP-Dependent Protein Kinases/genetics , Mesenchymal Stem Cells/metabolism , Parathyroid Hormone/genetics , Animals , Cell Differentiation , Chondrocytes/cytology , Collagen Type II/genetics , Collagen Type II/metabolism , Collagen Type X/genetics , Collagen Type X/metabolism , Core Binding Factor Alpha 2 Subunit/antagonists & inhibitors , Core Binding Factor Alpha 2 Subunit/metabolism , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Cyclic AMP-Dependent Protein Kinases/metabolism , Embryo, Mammalian , Gene Expression Regulation, Developmental , Limb Buds/cytology , Limb Buds/embryology , Limb Buds/metabolism , Mesenchymal Stem Cells/cytology , Mice , Parathyroid Hormone/metabolism , Protein Kinase Inhibitors/pharmacology , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Signal Transduction
5.
J Orthop Res ; 30(11): 1760-6, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22517267

ABSTRACT

Lead remains a significant environmental toxin, and we believe we may have identified a novel target of lead toxicity in articular chondrocytes. These cells are responsible for the maintenance of joint matrix, and do so under the regulation of TGF-ß signaling. As lead is concentrated in articular cartilage, we hypothesize that it can disrupt normal chondrocyte phenotype through suppression of TGF-ß signaling. These experiments examine the effects of lead exposure in vivo and in vitro at biologically relevant levels, from 1 nM to 10 µM on viability, collagen levels, matrix degrading enzyme activity, TGF-ß signaling, and articular surface morphology. Our results indicate that viability was unchanged at levels ≤100 µM Pb, but low and high level lead in vivo exposure resulted in fibrillation and degeneration of the articular surface. Lead treatment also decreased levels of type II collagen and increased type X collagen, in vivo and in vitro. Additionally, MMP13 activity increased in a dose-dependent manner. Active caspase 3 and 8 were dose-dependently elevated, and treatment with 10 µM Pb resulted in increases of 30% and 500%, respectively. Increasing lead treatment resulted in a corresponding reduction in TGF-ß reporter activity, with a 95% reduction at 10µM. Levels of phosphoSmad2 and 3 were suppressed in vitro and in vivo and lead dose-dependently increased Smurf2. These changes closely parallel those seen in osteoarthritis. Over time this phenotypic shift could compromise maintenance of the joint matrix.


Subject(s)
Cartilage, Articular/drug effects , Chondrocytes/drug effects , Lead/toxicity , Osteoarthritis/chemically induced , Transforming Growth Factor beta/metabolism , Animals , Cartilage, Articular/metabolism , Cell Line , Chickens , Chondrocytes/metabolism , Phenotype , Rats , Signal Transduction/drug effects , Toxicity Tests, Acute
6.
Calcif Tissue Int ; 89(4): 271-84, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21833848

ABSTRACT

The key to treating steroid-induced necrosis of femoral heads (SINFH) is early diagnosis. Dramatic improvements in diagnosis could be made if the pathogenesis of SINFH was more fully understood; however, the underlying mechanism of this disease is currently unknown. To explore the potential mechanism of SINFH, we performed gene array analysis on a rat model of the disease and compare the expression profile with that of normal rats. A quantitative RT-PCR and immunohistochemistry (IHC) assays were used to confirm the microarray results. Compared to the control group, 190 genes in the experimental group were differentially expressed, with 52 up-regulated and 138 down-regulated. Of these genes, 102 are known (deposited in GenBank), while 88 of them are unknown. The known genes can be divided into several families according to their biological functions, such as oxidative stress, apoptosis, signal transduction, angiogenesis, extracellular matrix, lipid metabolism, and transcription related genes. The results of quantitative RT-PCR and IHC were consistent with gene chip results. Our findings indicate that many genes involved in diverse signaling pathways were differentially expressed between SINFH rats and normal rats. Furthermore, our findings suggest that the development of SINFH is a complicated and dynamic process affected by multiple factors and signaling pathways and regulated by various genes.


Subject(s)
Femur Head Necrosis/chemically induced , Femur Head Necrosis/genetics , Gene Expression Profiling , Steroids/adverse effects , Animals , Biomarkers/analysis , Biomarkers/metabolism , Bone Marrow/metabolism , Bone Marrow/pathology , Bone and Bones/metabolism , Bone and Bones/pathology , Cluster Analysis , Disease Models, Animal , Femur Head Necrosis/diagnosis , Femur Head Necrosis/pathology , Glucocorticoids/adverse effects , Male , Microarray Analysis , Rats , Rats, Wistar , Time Factors
7.
Trials ; 12: 187, 2011 Aug 02.
Article in English | MEDLINE | ID: mdl-21806837

ABSTRACT

BACKGROUND: Osteoporosis is a growing worldwide problem, with the greatest burden resulting from fractures. Nevertheless, the majority of fractures in adults occur in those with "osteopenia" (bone mineral density (BMD) only moderately lower than young normal individuals). Since long-term drug therapy is an expensive option with uncertain consequences and side effects, natural herbal therapy offers an attractive alternative. The purpose of this study is to evaluate the effect on BMD and safety of the Classic Yin and Yang Tonic Formula for treatment of osteopenia and to investigate the mechanism by which this efficacy is achieved. METHODS/DESIGN: We propose a multicenter double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of the Classic Yin and Yang Tonic Formula for the treatment of osteopenia. Participants aged 55 to 75 with low bone mineral density (T-score between -1 and -2.5) and kidney deficiency in TCM will be included and randomly allocated into two groups: treatment group and control group. Participants in the treatment group will be treated with Classic Yin and Yang Tonic Granule, while the controlled group will receive placebo. Primary outcome measure will be BMD of the lumbar spine and proximal femur using dual-energy X-ray absorptiometry. Secondary outcomes will include pain intensity measured with visual analogue scales, quality of life, serum markers of bone metabolism, indices of Neuro-endocrino-immune network and safety. DISCUSSION: If the Classic Yin and Yang Tonic Formula can increase bone mass without adverse effects, it may be a novel strategy for the treatment of osteoporosis. Furthermore, the mechanism of the Chinese medical formula for osteoporosis will be partially elucidated. TRIAL REGISTRATION: This study is registered at ClinicalTrials.gov, NCT01271647.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Diseases, Metabolic/drug therapy , Drugs, Chinese Herbal/therapeutic use , Research Design , Yin-Yang , Absorptiometry, Photon , Aged , Biomarkers/blood , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/complications , Bone Diseases, Metabolic/diagnostic imaging , Bone Remodeling/drug effects , China , Double-Blind Method , Drugs, Chinese Herbal/adverse effects , Femur/diagnostic imaging , Femur/drug effects , Fractures, Bone/etiology , Fractures, Bone/prevention & control , Humans , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/drug effects , Middle Aged , Pain/etiology , Pain/prevention & control , Pain Measurement , Placebo Effect , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Time Factors , Treatment Outcome
8.
J Bone Miner Res ; 22(10): 1571-80, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17576166

ABSTRACT

UNLABELLED: The AHR mediates many of the toxicological effects of aromatic hydrocarbons. We show that AHR expression in osteoblasts parallels the induction of early bone-specific genes involved in maturation. The AHR may not only mediate the effects of toxicants, but with an as yet unidentified ligand, be involved in the differentiation pathways of osteoblasts. INTRODUCTION: Metabolic bone diseases arise as a result of an imbalance in bone cell activities. Recent evidence suggests that environmental toxicants may be contributing factors altering these activities. One candidate molecule implicated in mediating the toxic effects of exogenous compounds is the aryl hydrocarbon receptor (AHR). MATERIALS AND METHODS: Osteoblasts isolated from neonatal rat calvaria were analyzed for AHR expression by quantitative PCR, Western blot, and immunohistochemistry. In addition, AHR activation was evaluated by electromobility gel shift assay and fluorescence microscopy. RESULTS: Our findings showed AHR expression in mature osteoblasts in vivo. The pattern of AHR expression peaks after alkaline phosphatase and before induction of osteocalcin. We first show that AHR functions as a transactivating receptor in osteoblasts, as evidenced by its ligand-dependent migration to the nucleus and its association with known dioxin response elements. AHR activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) mediated the induction of cytochrome p450 1A1 and cycloxygenase-2 protein levels. This effect could be inhibited by the potent AHR antagonist, 3'4 methoxynitroflavone. Furthermore, lead treatment of osteoblasts upregulates the expression of AHR mRNA and protein levels, supporting a novel mechanism whereby lead in the skeleton may increase the sensitivity of bone cells to toxicant exposure. CONCLUSIONS: These data imply that the AHR mediates the effects of aromatic toxicants on bone and that AHR expression is regulated during osteoblast differentiation.


Subject(s)
Cell Differentiation/drug effects , Hazardous Substances/pharmacology , Osteoblasts/drug effects , Osteoblasts/metabolism , Polychlorinated Dibenzodioxins/pharmacology , Receptors, Aryl Hydrocarbon/metabolism , Alkaline Phosphatase/metabolism , Animals , Cells, Cultured , Cyclooxygenase 2/metabolism , Cytochrome P-450 CYP1A1/metabolism , Enzyme Activation/drug effects , Male , Mice , Mice, Knockout , Osteoblasts/cytology , Rats , Receptors, Aryl Hydrocarbon/deficiency , Receptors, Aryl Hydrocarbon/genetics , Transcriptional Activation/genetics , Up-Regulation
9.
Birth Defects Res C Embryo Today ; 81(1): 41-50, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17539012

ABSTRACT

In this treatise we will examine complexities in the development and function of cells of the musculoskeletal system. Specifically, the role of chondrocytes and their ontogeny and osteoblasts and their ontogeny will be discussed as they regulate cartilage and bone formation. This background information will provide the foundation for evaluating the effects of environmental toxicants on skeletal development. A number of agents such as heavy metals (i.e. lead) and polycyclic aromatic hydrocarbons (i.e. pesticides and cigarette smoke) interact with cells of the skeletal system and adversely affect development. These agents have not been of major research interest, nevertheless, given changes in the environmental profile of the United States and other developed countries, it is important that we understand their effects in bone and cartilage. Research in this area will identify strategies that may be used to help prevent musculoskeletal diseases due to toxicant exposure.


Subject(s)
Bone Development/drug effects , Environmental Pollutants/toxicity , Animals , Chondrocytes/cytology , Chondrocytes/drug effects , Chondrogenesis/drug effects , Humans , Lead Poisoning/complications , Lead Poisoning/pathology , Metals, Heavy/toxicity , Osteoarthritis/etiology , Osteoblasts/cytology , Osteoblasts/drug effects , Osteogenesis/drug effects , Polycyclic Aromatic Hydrocarbons/toxicity , Receptors, Aryl Hydrocarbon/drug effects , Receptors, Aryl Hydrocarbon/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...